Hvis en graviditet diagnosticeres eller planlægges, bør behandlingen tages op til nøje overvejelse, og patienten skal oplyses om den mulige teratogene risiko ved cysteamin.
If a pregnancy is diagnosed or planned, the treatment should be carefully reconsidered and the patient must be advised of the possible teratogenic risk of cysteamine.